3/7
08:14 am
imab
I-Mab Announces Accelerated Givastomig Phase 1b Study Progress [Yahoo! Finance]
High
Report
I-Mab Announces Accelerated Givastomig Phase 1b Study Progress [Yahoo! Finance]
3/7
07:00 am
imab
I-Mab Announces Accelerated Givastomig Phase 1b Study Progress
Low
Report
I-Mab Announces Accelerated Givastomig Phase 1b Study Progress
3/1
05:58 am
imab
I-Mab (NASDAQ: IMAB) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
Low
Report
I-Mab (NASDAQ: IMAB) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
2/18
07:00 am
imab
I-Mab to Participate in Leerink Partners Global Healthcare Conference
Low
Report
I-Mab to Participate in Leerink Partners Global Healthcare Conference
2/4
08:50 am
imab
In This Article : [Yahoo! Finance]
Neutral
Report
In This Article : [Yahoo! Finance]
2/4
07:30 am
imab
I-Mab to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
Low
Report
I-Mab to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
1/8
09:22 am
imab
I-Mab announces open market purchases by board member [Seeking Alpha]
Low
Report
I-Mab announces open market purchases by board member [Seeking Alpha]
1/8
07:00 am
imab
I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member
Medium
Report
I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member
1/6
07:12 am
imab
In This Article : [Yahoo! Finance]
High
Report
In This Article : [Yahoo! Finance]
1/6
07:00 am
imab
I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program
High
Report
I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program